External scientific grant reviews provide an essential service to organizations that fund global research. Consequently, it is an aim of the Breast Health Global Initiative (BHGI) to be part of the process that encourages funding of international research.
An international research program established in 2008 by GlaxoSmithKline Oncology (GSK), called the Ethnic Research Initiative (ERI), provided BHGI the first opportunity to organize and manage a scientific review of grant applications submitted through the ERI grant mechanism. Co-chaired by Dr. Anderson and Peggy Porter, MD, a 14-member BHGI Scientific Review Committee met at the Fred Hutchinson Cancer Research Center in Seattle in October 2011 to review 23 grant applications. Dr. Porter is Full Member in the Divisions of Human Biology and Public Health Sciences, and Head of Breast Cancer Research Program at the Fred Hutchinson Cancer Research Center and Professor of the Department of Pathology, University of Washington.
The long-term goal of the ERI is to help reduce breast cancer incidence, morbidity and mortality in ethnically diverse populations of the world. ERI grant funding builds on a previous GSK funded study that surveyed breast cancer opinion leaders in medicine, policy and advocacy from 30 countries. A key study finding was a reported higher breast cancer incidence, with more aggressive tumors, in younger women in non-Western populations compared to Western populations. The study also identified the need for basic research and national registries to validate these observations. The new grant funding will target basic and applied research in non-Western populations.
Four successful reviews have been completed, the most recent being October 7-8, 2011. Conducted by the Breast Health Global Initiative (BHGI), the 14-member review committee met at the Fred Hutchinson Cancer Research Center in Seattle, for the review of the 23 international final applications.
PHOTO: From left, 2009 GSK Ethnic Research Initiative (ERI) Grant Recipients: Dr. Sudeep Gupta, Dr. Shona Nag (India), Dr. Patricia Ashton-Prolla (Brazil), Dr. Virote Sriuranapong (Thailand), with GSK ERI Internal Steering Committee co-Chairs Dr. Antonio Carlos Buzaid, Oncology Center, Hospital Sirio-Libanés, San Pablo, Brazil, Dr. Peggy Porter, Fred Hutchinson Cancer Research Center, Seattle, Washington and Dr. Jorge Otero, GlaxoSmithKline, Collegeville, Pennsylvania.